Chronic spontaneous urticaria places a heavier burden on patients than atopic dermatitis and psoriasis, leading to a worse ...

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

Digitization has allowed Sanofi to optimize manufacturing and automate document preparation. And now, the firm predicts that ...

As the future of rare disease research at Cincinnati Children's is threatened, parents of 13-year-old Charlie Evans plead for its reinstatement.

Sanofi’s latest earnings call reflects a positive outlook for the company, marked by strong sales growth, strategic acquisitions, and a commitment to sustainability. Despite some challenges, such as ...

Regeneron topped Wall Street estimates for second-quarter results on Friday, on robust demand for its blockbuster eczema drug ...

Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...

Delays in the decision dates for high-dose Eylea are linked to issues at a Catalent-owned facility. Once these are resolved, ...

Sanofi missed analyst projections of $1.32 with Q2 earnings per share (EPS) of $1.25. Revenue was €9.89 billion, which was ...

On Friday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported second-quarter adjusted earnings of $12.89 per share, up 12% ...

(Reuters) -Regeneron Pharmaceuticals beat Wall Street estimates for second-quarter revenue and profit on Friday helped by ...

Although Sanofi delivered an earnings miss which still had encouraging results, SNY stock tanked, offering a potential ...